Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
about
Pneumococcal conjugate vaccines for preventing otitis mediaPneumococcal conjugate vaccines for preventing otitis mediaPneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of agePneumococcal vaccines for preventing otitis mediaProspects for vaccine prevention of meningococcal infectionExploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines.Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure dataIntranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection.Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae.Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.The pharmacist's role in promoting optimal antimicrobial use.Emergence of penicillin-nonsusceptible Streptococcus pneumoniae invasive clones in Canada.Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study.Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides.Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccineImmunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants.Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.New pneumococcal vaccines for children.Fever following immunization.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests.Current state of pneumococcal vaccines.Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model.Antibiotic-resistant invasive pediatric Streptococcus pneumoniae clones in Israel.Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM₁₉₇ conjugate vaccine.Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.Genetic variation influences the B-cell response to immunization with a pneumococcal polysaccharide conjugate vaccineVaccines based on the cell surface carbohydrates of pathogenic bacteria.Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines.
P2860
Q24197520-6A547B17-6B62-4760-9A72-E9DBD48614F2Q24241287-4859F375-3535-4A1F-8F7C-596DA4F68A9DQ24245934-2D77B82C-C52D-4E1C-923F-3033B6EAD999Q24247465-2023FF4E-5640-4BDB-9188-0B7CE372C662Q24537338-64819883-100D-448D-8DD2-FA8B0FC77732Q30559887-740143E9-D4A2-4299-9848-556E66359B75Q30665602-D5670EFC-BBBD-4E20-9553-B2B12FE51B86Q31158788-409EA249-E8E4-490A-A6E0-0545CEE9EAD9Q33552360-2E1F4994-76DC-4852-84F4-E3588609BCF2Q33557154-120122F9-B816-41DB-A83E-C38FAA4EE70FQ33592652-7DCE9E32-E1C3-40DC-A8CD-9E374D466B20Q33792707-9AE62DC6-6FF0-4573-8B04-FA5FA96D0FAFQ33942876-D8A6F77E-5B4E-4771-9BFF-C7B767CA12F3Q33946065-A11BF614-1714-4F03-B1A3-05A791CC4463Q33963100-95D283D4-9423-4EF5-A752-22C57D8AA8D0Q33973455-D55D093C-96FD-4A97-802F-1EDEC033059BQ34003306-BC2CF1D7-DDB5-4636-8FEA-10CFC3915692Q34003589-BF6E31BC-2183-4272-97AD-7AF1C2825183Q34072420-F6C87356-4662-4533-A416-F9E7A087C117Q34092415-F023416F-C3C1-4971-B77C-29165B821C51Q34120949-92083639-D5CD-4B5C-9B92-BB5B86B4B280Q34129863-BC584E01-CAE6-40D5-9737-0647CA939B20Q34170021-044E6FCC-0EC9-4162-8401-3C74C3A4954EQ34175136-3CBF7D6B-23FB-47E1-8B5C-5038EF605C47Q34179527-593814E0-2D35-4F2F-AD2E-BD5B4E60FC82Q34190093-0DF52ECC-E1D9-4651-AA22-CBB51FDB0070Q34434824-345DD39D-47B8-40A5-ABA5-F04C75182BFDQ34487139-127DDB46-40A7-470D-BE5E-BB7212228D82Q34632848-11D4A65D-4E78-415E-8306-5727F2361EEFQ34744239-A21A8496-6B27-4C73-A60D-D7F1CE98BE37Q34774773-6BCFF8C6-91EF-4DFE-9F11-F01A468F26B3Q34935287-2AB41D52-FE78-4015-A21D-932A66481C50Q34949753-544617CD-9D53-4EBD-9E01-DB88183D5780Q35066102-C410F7AD-F189-4F02-9437-D9D6802885E3Q35783918-48672100-D5D0-4D59-9A0E-E6585FE53158Q35802204-6A3FE851-E9C1-4BAA-BACD-43E4EF9D7D8BQ36128243-35A45C0C-D478-4275-8F06-3DBECD590AC4Q36154661-522BF680-212C-4383-9A02-AE797BCB5E3AQ36156085-E3284E22-2EAA-4EB5-BCC9-6775C7AA41F4Q36287530-0D53E23F-C1F2-49A3-A445-DDC3233072D4
P2860
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@ast
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@en
type
label
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@ast
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@en
prefLabel
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@ast
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@en
P2093
P1476
Safety and immunogenicity of h ...... ccine in infants and toddlers.
@en
P2093
Kohberger R
P304
P356
10.1097/00006454-199909000-00004
P577
1999-09-01T00:00:00Z